Genomic biomarkers for cutaneous T-cell Lymphoma

皮肤 T 细胞淋巴瘤的基因组生物标志物

基本信息

  • 批准号:
    10703843
  • 负责人:
  • 金额:
    $ 17.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-10-01 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Peripheral T-cell lymphomas including cutaneous T-cell lymphomas (CTCL) are poorly understood and many subtypes exhibit aggressive clinical course and high mortality with short (2-year) life expectancy after diagnosis. Poor understanding of mechanisms underlying the pathogenesis of CTCLs contributes to suboptimal diagnostic subcategorization and lack of targeted therapies. Mycosis fungoides (MF) and Sezary syndrome (SS) are two major forms of CTCL. Clinical staging and outcome of MF and SS is dependent on the quantity of neoplastic cells in the blood. While SS is an aggressive disease with poor overall survival (42.3% at 5 years and is by definition diagnosed at late stage disease, there are many patients with low tumor burden (Early-stage CTCL) who suffer from delay in diagnosis due to the subjective nature of the diagnostic criteria. The mean diagnostic delay (measured as the time from emergence of skin lesions to the diagnosis of SS) is long (4.2 year; median 2.8 years) with a significant variation (1 month to 32 years). Thus, there is a critical need for improved methods for early disease detection. Furthermore, the identification of genomic disease biomarkers that would establish early diagnosis and provide prognostic information would clearly have benefit for patients with this form of aggressive CTCL. Until recently, recurrent genetic alterations that can be exploited as diagnostic and prognostic biomarkers have not been described in these tumors. Our laboratory and other investigators recently described the genomic landscape of CTCL utilizing a comprehensive integrated strategy including whole genome sequencing, whole exome sequencing and array comparative gnomic hybridization. Highly recurrent gene mutations targeting epigenetic and chromatin remodeling and JAK-STAT and other pathways were identified in pre- treatment samples of CTCL. Based on these results, it is our central hypothesis that somatic alterations involved in the pathogenesis of CTCL in conjunction with high-throughput sequencing (HTS) of the T-cell receptor (TCR) can be utilized for early diagnosis and that genetic profiles and sensitive and quantitative detection of clonal T-cell populations can serve as prognostically-relevant biomarkers of CTCL. Accordingly, in Specific Aim 1, we propose to investigate the utility of a multivariate model based on targeted next generation sequencing (NGS) and HTS-TCR assays for the diagnosis of ES-CTCL and Late- stage CTCL (SS). In Specific Aim 2, we will investigate the impact of the genetic mutations and HTS-TCR on the prognosis of ES-CTCL and SS using a retrospective cohort. In Specific Aim 3, we will assess the performance of the multivariate model for assessing the prognosis of ES-CTCL and SS using a prospective cohort. The overall impact of this proposal is the development of targeted genomic assays that will lead to early and accurate diagnosis of CTCL and improve methods to assess early disease detection and prognosis.
项目摘要 外周T细胞淋巴瘤,包括皮肤T细胞淋巴瘤(CTCL)了解甚少,许多 亚型表现出侵略性的临床过程和高死亡率,预期寿命短(2年), 诊断.对CTCL发病机制的认识不足有助于 次优诊断亚分类和缺乏靶向治疗。蕈样肉芽肿(MF)和Sezary 综合征(SS)是CTCL两种主要形式。MF和SS的临床分期和结局取决于 血液中肿瘤细胞的数量虽然SS是一种侵袭性疾病, (42.3%,并且根据定义在晚期疾病时被诊断,有许多患者具有低 肿瘤负荷(早期CTCL),由于主观性质而导致诊断延迟。 诊断标准平均诊断延迟(测量为从皮肤病变出现到 诊断为SS)的时间较长(4.2年;中位数2.8年),具有显著变化(1个月至32年)。 因此,迫切需要用于早期疾病检测的改进方法。而且 鉴定基因组疾病生物标志物,其将建立早期诊断并提供预后 这些信息显然对患有这种形式的侵袭性CTCL的患者有益。直到最近, 可用作诊断和预后生物标志物的复发性遗传改变尚未被 描述了这些肿瘤。我们的实验室和其他研究人员最近描述了基因组 利用包括全基因组测序在内的全面综合战略的CTCL前景, 全外显子组测序和阵列比较基因组杂交。高度重复发生的基因突变 靶向表观遗传和染色质重塑以及JAK-STAT和其他途径, CTCL的治疗样品。基于这些结果,我们的中心假设是, 参与CTCL发病机制的T细胞高通量测序(HTS) 受体(TCR)可用于早期诊断,基因谱和敏感性, 克隆T细胞群的定量检测可以作为免疫学相关的生物标志物, CTCL。因此,在具体目标1中,我们建议研究基于以下的多变量模型的效用: 靶向下一代测序(NGS)和HTS-TCR测定用于诊断ES-CTCL和晚期- CTCL(SS)期。在具体目标2中,我们将研究基因突变和HTS-TCR的影响。 ES-CTCL和SS的预后。在具体目标3中,我们将评估 多变量模型用于评估ES-CTCL和SS预后的性能, 前瞻性队列这一提议的总体影响是靶向基因组测定的发展, 将导致CTCL的早期和准确诊断,并改善评估早期疾病检测的方法 和预后。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Megan S. Lim其他文献

Pilot Study Using Induction Chemo-Immunotherapy Followed By Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T- or NK-Cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults
  • DOI:
    10.1182/blood-2022-160045
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Ana C. Xavier;Lauren Harrison;Rodney R. Miles;Stephan Voss;Megan S. Lim;Mitchell S. Cairo
  • 通讯作者:
    Mitchell S. Cairo
Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines
  • DOI:
    10.1182/blood-2022-170360
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Sheila K Pierson;Mateo Sarmiento Bustamante;Joshua D Brandstadter;Daisy Alapat;Adam Bagg;Mary Jo Lechowicz;Gordan Srkalovic;Megan S. Lim;Frits van Rhee;David C Fajgenbaum
  • 通讯作者:
    David C Fajgenbaum
Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy
  • DOI:
    10.1182/blood-2022-165086
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Danielle F Soberman;Jennifer J.D. Morrissette;Stephen J. Schuster;Sunita Dwivedy Nasta;James N. Gerson;Stefan K. Barta;Jakub Svoboda;Elise A. Chong;Megan S. Lim;Daniel J. Landsburg
  • 通讯作者:
    Daniel J. Landsburg
The Diagnostic Utility of TRBC1 Immunohistochemistry in Mature T-Cell Lymphomas
TRBC1免疫组织化学在成熟T细胞淋巴瘤中的诊断效用
  • DOI:
    10.1016/j.modpat.2025.100725
  • 发表时间:
    2025-06-01
  • 期刊:
  • 影响因子:
    5.500
  • 作者:
    Ting Zhou;Rohan Sardana;Ozgur Can Eren;Melissa Pulitzer;Achim Jungbluth;Ahmet Dogan;Megan S. Lim
  • 通讯作者:
    Megan S. Lim
The <em>NPM1</em>-<em>TYK2</em> Chimeric Fusion Promotes Activation of STAT Family Signaling, Skewing Towards Tfh Functional Subset Differentiation and Mature T-Cell Lymphomagenesis
  • DOI:
    10.1182/blood-2022-169494
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Huang-Chang Liang;Richa Kapoor;Ozlem Onder;Kevin Dennis;Megan S. Lim;Kojo S.J. Elenitoba-Johnson
  • 通讯作者:
    Kojo S.J. Elenitoba-Johnson

Megan S. Lim的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Megan S. Lim', 18)}}的其他基金

Genomic biomarkers for cutaneous T-cell Lymphoma
皮肤 T 细胞淋巴瘤的基因组生物标志物
  • 批准号:
    10550139
  • 财政年份:
    2022
  • 资助金额:
    $ 17.46万
  • 项目类别:
Circulating biomarkers of ALK+ anaplastic large cell lymphoma
ALK 间变性大细胞淋巴瘤的循环生物标志物
  • 批准号:
    10703855
  • 财政年份:
    2022
  • 资助金额:
    $ 17.46万
  • 项目类别:
Circulating biomarkers of ALK+ anaplastic large cell lymphoma
ALK 间变性大细胞淋巴瘤的循环生物标志物
  • 批准号:
    10680558
  • 财政年份:
    2022
  • 资助金额:
    $ 17.46万
  • 项目类别:
Circulating biomarkers of ALK+ anaplastic large cell lymphoma
ALK 间变性大细胞淋巴瘤的循环生物标志物
  • 批准号:
    10298658
  • 财政年份:
    2021
  • 资助金额:
    $ 17.46万
  • 项目类别:
Circulating biomarkers of ALK+ anaplastic large cell lymphoma
ALK 间变性大细胞淋巴瘤的循环生物标志物
  • 批准号:
    10470371
  • 财政年份:
    2021
  • 资助金额:
    $ 17.46万
  • 项目类别:
Genomic biomarkers for cutaneous T-cell Lymphoma
皮肤 T 细胞淋巴瘤的基因组生物标志物
  • 批准号:
    10321292
  • 财政年份:
    2020
  • 资助金额:
    $ 17.46万
  • 项目类别:
Genomic biomarkers for cutaneous T-cell Lymphoma
皮肤 T 细胞淋巴瘤的基因组生物标志物
  • 批准号:
    9884667
  • 财政年份:
    2020
  • 资助金额:
    $ 17.46万
  • 项目类别:
Proteomic biomarkers of ALK+ lymphoma
ALK 淋巴瘤的蛋白质组生物标志物
  • 批准号:
    8385569
  • 财政年份:
    2009
  • 资助金额:
    $ 17.46万
  • 项目类别:
Proteomic biomarkers of ALK+ lymphoma
ALK 淋巴瘤的蛋白质组生物标志物
  • 批准号:
    7790983
  • 财政年份:
    2009
  • 资助金额:
    $ 17.46万
  • 项目类别:
Proteomic biomarkers of ALK+ lymphoma
ALK 淋巴瘤的蛋白质组生物标志物
  • 批准号:
    8196784
  • 财政年份:
    2009
  • 资助金额:
    $ 17.46万
  • 项目类别:

相似国自然基金

greenwashing behavior in China:Basedon an integrated view of reconfiguration of environmental authority and decoupling logic
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    万元
  • 项目类别:
    外国学者研究基金项目

相似海外基金

Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
  • 批准号:
    2876993
  • 财政年份:
    2027
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Studentship
Collaborative Research: Chain Transform Fault: Understanding the dynamic behavior of a slow-slipping oceanic transform system
合作研究:链变换断层:了解慢滑海洋变换系统的动态行为
  • 批准号:
    2318855
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Continuing Grant
Collaborative Research: Subduction Megathrust Rheology: The Combined Roles of On- and Off-Fault Processes in Controlling Fault Slip Behavior
合作研究:俯冲巨型逆断层流变学:断层上和断层外过程在控制断层滑动行为中的综合作用
  • 批准号:
    2319848
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Standard Grant
Collaborative Research: Subduction Megathrust Rheology: The Combined Roles of On- and Off-Fault Processes in Controlling Fault Slip Behavior
合作研究:俯冲巨型逆断层流变学:断层上和断层外过程在控制断层滑动行为中的综合作用
  • 批准号:
    2319849
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Standard Grant
MCA Pilot PUI: From glomeruli to pollination: vertical integration of neural encoding through ecologically-relevant behavior
MCA Pilot PUI:从肾小球到授粉:通过生态相关行为进行神经编码的垂直整合
  • 批准号:
    2322310
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Continuing Grant
CAREER: A cortex-basal forebrain loop enabling task-specific cognitive behavior
职业:皮层基底前脑环路实现特定任务的认知行为
  • 批准号:
    2337351
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Continuing Grant
Conference: 2024 Photosensory Receptors and Signal Transduction GRC/GRS: Light-Dependent Molecular Mechanism, Cellular Response and Organismal Behavior
会议:2024光敏受体和信号转导GRC/GRS:光依赖性分子机制、细胞反应和生物体行为
  • 批准号:
    2402252
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Standard Grant
Nanoscopic elucidation of dynamic behavior of RNA viral nucleocapsid proteins using high-speed atomic force microscopy (HS-AFM)
使用高速原子力显微镜 (HS-AFM) 纳米级阐明 RNA 病毒核衣壳蛋白的动态行为
  • 批准号:
    24K18449
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERI: Data-Driven Analysis and Dynamic Modeling of Residential Power Demand Behavior: Using Long-Term Real-World Data from Rural Electric Systems
ERI:住宅电力需求行为的数据驱动分析和动态建模:使用农村电力系统的长期真实数据
  • 批准号:
    2301411
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Standard Grant
Understanding the synthesis and electronic behavior of beta tungsten thin film materials
了解β钨薄膜材料的合成和电子行为
  • 批准号:
    23K20274
  • 财政年份:
    2024
  • 资助金额:
    $ 17.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了